Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Vivus grants Menarini marketing rights to Spedra in Europe, Australia, and New Zealand

Executive Summary

Menarini Group has received rights to market Vivus Inc.’s (focused on sexual health and metabolic and respiratory conditions) Spedra (avanafil) in over 40 European countries, Australia, and New Zealand. Spedra is a phosphodiesterase-5 inhibitor that was approved in the US in early 2012 (as Stendra) and in Europe last month for erectile dysfunction.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Manufacturing or Supply
    • Marketing (Licensing)

Related Companies